U.S. Biotech on the Brink of Lung Cancer Targeted Drug, CSO Sells Stock Options for Billions in Profit

On March 12, Henry E. Pelish, Chief Scientific Officer of U.S. clinical-stage biopharmaceutical company Nuvalent, Inc. (NASDAQ: NUVL), exercised multiple tranches of stock options to acquire roughly 17,000 shares, then sold about 35,000 shares on the open market over March 12–13. The shares traded at approximately $97.80–$99.70 each, generating total proceeds of about $3.46 million (≈KRW 4.5 billion). Following the transaction, he continues to hold approximately 65,000 shares.

On January 12, Nuvalent published an update on its “OnTarget 2026” operating plan, reaffirming key clinical and regulatory milestones aimed at securing its first oncology approval and commercial launch by 2026. Late last year, the company also strengthened its commercialization readiness and pipeline development by adding oncology veteran Ron Squarer to its board of directors. (investors.nuvalent.com)

Headquartered in Cambridge, Massachusetts, Nuvalent is a precision-oncology biotech developing small-molecule kinase inhibitors that target specific genetic mutations in cancers such as lung cancer. Its lead pipeline candidates include the ROS1 inhibitor zidesamtinib, the ALK inhibitor neladalkib, and the HER2-targeting NVL-330—all advancing through clinical and regulatory stages with an official goal of first product approval in 2026. (nuvalent.com)